Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: 10.1210/clinem/dgaa049
- Event
-
Veröffentlichung
- (where)
-
Aachen
- (who)
-
Universitätsbibliothek der RWTH Aachen
- (when)
-
2020
- Creator
-
Johannsson, Gudmundur
Gordon, Murray B.
Højby Rasmussen, Michael
Håkonsson, Ida Holme
Karges, Wolfram
Sværke, Claus
Tahara, Shigeyuki
Takano, Koji
Biller, Beverly M. K.
- DOI
-
10.18154/RWTH-2020-04927
- URN
-
urn:nbn:de:101:1-2020111307351256274488
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Johannsson, Gudmundur
- Gordon, Murray B.
- Højby Rasmussen, Michael
- Håkonsson, Ida Holme
- Karges, Wolfram
- Sværke, Claus
- Tahara, Shigeyuki
- Takano, Koji
- Biller, Beverly M. K.
- Universitätsbibliothek der RWTH Aachen
Time of origin
- 2020
Other Objects (12)
Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
Treatment responses with once-weekly teriparatide therapy for osteoporosis
Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent
Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis
Enhanced disulphide bond stability contributes to the once-weekly profile of insulin icodec
Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study
Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates
Real-world use of once-weekly semaglutide in type 2 diabetes: results from SURE Germany
Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes
Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
Treatment responses with once-weekly teriparatide therapy for osteoporosis
Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent
Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis
Enhanced disulphide bond stability contributes to the once-weekly profile of insulin icodec
Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study
Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates
Real-world use of once-weekly semaglutide in type 2 diabetes: results from SURE Germany
Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes
Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
Treatment responses with once-weekly teriparatide therapy for osteoporosis
Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent
Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis
Enhanced disulphide bond stability contributes to the once-weekly profile of insulin icodec
Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study
Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates
Real-world use of once-weekly semaglutide in type 2 diabetes: results from SURE Germany